Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CervoMed Inc.CRVO · Entity 7338 | Director · 10% owner | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CervoMed Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trusts | 1,795,865 |
Reported balance
After 2026-06-11 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-11 · Purchase · Acquired 955,414 · Balance 1,795,865 F1: On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase Agreement"), with the Joshua S. Boger 2021 Trust DTD 12/09/2021, of which the Reporting Person serves as the sole trustee (the "JSB 2021 Trust"), and certain accredited investors named therein. Pursuant to the Purchase Agreement, the JSB 2021 Trust purchased an aggregate of 955,414 units (the "Units"), each Unit comprised of (i) one share of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) one Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series B Warrant"), and (iii) one Series C warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series C Warrant") for a purchase price of $3.14 per Unit. F2: After giving effect to all transactions described herein, consists of (i) 1,600,117 shares of the Issuer's common stock held by the JSB 2021 Trust and (ii) 195,748 shares of the Issuer's common stock held by The Amy S. Boger 2021 Trust (the "ASB 2021 Trust"). The Reporting Person serves as the sole trustee of each of the JSB 2021 Trust and the ASB 2021 Trust. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
| Series B WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $3.32 · Expires 2031-06-11 | IndirectBy Trust | 955,414 |
Reported balance
After 2026-06-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-11 · Purchase · Acquired 955,414 · Balance 955,414 F3: The Series B Warrants have an exercise price equal to $3.32 per share of Common Stock or $3.319 per pre-funded warrant, are exercisable immediately, and will expire five years from the issuance date of the Series B Warrant. F5: Under the terms of the Series B Warrants and the Series C Warrants, the Issuer may not effect the exercise of any portion thereof, and the JSB 2021 Trust will not have the right to exercise any portion thereof, which, upon giving effect to such exercise, would cause the JSB 2021 Trust (together with its affiliates) to own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. To the extent that exercise of the Series B Warrants or Series C Warrants will result in the JSB 2021 Trust (together with its affiliates) beneficially owning shares of Common Stock above such ownership limitations, the JSB 2021 Trust may exercise its Series B Warrants or Series C Warrants for pre-funded warrants to purchase shares of Common Stock, which pre-funded warrants will include a substantially similar maximum ownership limitation. F1: On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase Agreement"), with the Joshua S. Boger 2021 Trust DTD 12/09/2021, of which the Reporting Person serves as the sole trustee (the "JSB 2021 Trust"), and certain accredited investors named therein. Pursuant to the Purchase Agreement, the JSB 2021 Trust purchased an aggregate of 955,414 units (the "Units"), each Unit comprised of (i) one share of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) one Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series B Warrant"), and (iii) one Series C warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series C Warrant") for a purchase price of $3.14 per Unit. F6: The Series B Warrants and Series C Warrants are owned by the JSB 2021 Trust. |
| Series C WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $3.14 · Expires 2027-06-11 | IndirectBy Trust | 955,414 |
Reported balance
After 2026-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-11 · Purchase · Acquired 955,414 · Balance 955,414 F4: The Series C Warrants have an exercise price equal to $3.14 per share of Common Stock or $3.139 per pre-funded warrant, are exercisable immediately, and will expire one year from the issuance date of the Series C Warrant. F5: Under the terms of the Series B Warrants and the Series C Warrants, the Issuer may not effect the exercise of any portion thereof, and the JSB 2021 Trust will not have the right to exercise any portion thereof, which, upon giving effect to such exercise, would cause the JSB 2021 Trust (together with its affiliates) to own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. To the extent that exercise of the Series B Warrants or Series C Warrants will result in the JSB 2021 Trust (together with its affiliates) beneficially owning shares of Common Stock above such ownership limitations, the JSB 2021 Trust may exercise its Series B Warrants or Series C Warrants for pre-funded warrants to purchase shares of Common Stock, which pre-funded warrants will include a substantially similar maximum ownership limitation. F1: On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase Agreement"), with the Joshua S. Boger 2021 Trust DTD 12/09/2021, of which the Reporting Person serves as the sole trustee (the "JSB 2021 Trust"), and certain accredited investors named therein. Pursuant to the Purchase Agreement, the JSB 2021 Trust purchased an aggregate of 955,414 units (the "Units"), each Unit comprised of (i) one share of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) one Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series B Warrant"), and (iii) one Series C warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series C Warrant") for a purchase price of $3.14 per Unit. F6: The Series B Warrants and Series C Warrants are owned by the JSB 2021 Trust. |
| Common StockSEC Table I · non-derivative | Direct | 216,817 |
Reported balance
Holding disclosure · report date 2026-06-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 216,817 |
Filing footnotes · ownership attribution and instrument terms
F1: On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase Agreement"), with the Joshua S. Boger 2021 Trust DTD 12/09/2021, of which the Reporting Person serves as the sole trustee (the "JSB 2021 Trust"), and certain accredited investors named therein. Pursuant to the Purchase Agreement, the JSB 2021 Trust purchased an aggregate of 955,414 units (the "Units"), each Unit comprised of (i) one share of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) one Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series B Warrant"), and (iii) one Series C warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series C Warrant") for a purchase price of $3.14 per Unit.
F2: After giving effect to all transactions described herein, consists of (i) 1,600,117 shares of the Issuer's common stock held by the JSB 2021 Trust and (ii) 195,748 shares of the Issuer's common stock held by The Amy S. Boger 2021 Trust (the "ASB 2021 Trust"). The Reporting Person serves as the sole trustee of each of the JSB 2021 Trust and the ASB 2021 Trust. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F3: The Series B Warrants have an exercise price equal to $3.32 per share of Common Stock or $3.319 per pre-funded warrant, are exercisable immediately, and will expire five years from the issuance date of the Series B Warrant.
F4: The Series C Warrants have an exercise price equal to $3.14 per share of Common Stock or $3.139 per pre-funded warrant, are exercisable immediately, and will expire one year from the issuance date of the Series C Warrant.
F5: Under the terms of the Series B Warrants and the Series C Warrants, the Issuer may not effect the exercise of any portion thereof, and the JSB 2021 Trust will not have the right to exercise any portion thereof, which, upon giving effect to such exercise, would cause the JSB 2021 Trust (together with its affiliates) to own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. To the extent that exercise of the Series B Warrants or Series C Warrants will result in the JSB 2021 Trust (together with its affiliates) beneficially owning shares of Common Stock above such ownership limitations, the JSB 2021 Trust may exercise its Series B Warrants or Series C Warrants for pre-funded warrants to purchase shares of Common Stock, which pre-funded warrants will include a substantially similar maximum ownership limitation.
F6: The Series B Warrants and Series C Warrants are owned by the JSB 2021 Trust.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
VERTEX PHARMACEUTICALS INC / MA
Report date June 08, 2017 · Filed June 09, 2017
Section 16 reporting ended · disclosed 2017-06-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 284,088 |
Reported balance
After 2017-06-08 transaction · row 1
1 source rowRow 1 · 2017-06-08 · Exercise / conversion · Acquired 2,941 · Balance 284,088 F1: Each deferred stock unit represents one share of common stock and converted into common stock upon the termination of Dr. Boger's service on our board of directors on 06/08/2017. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-06-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-06-08 · Exercise / conversion · Disposed 2,941 · Balance 0 F1: Each deferred stock unit represents one share of common stock and converted into common stock upon the termination of Dr. Boger's service on our board of directors on 06/08/2017. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 13,286 |
Reported balance
Holding disclosure · report date 2017-06-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 13,286 |
| Common StockSEC Table I · non-derivative | IndirectCommon Stock Held In Trust | 64,525 |
Reported balance
Holding disclosure · report date 2017-06-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 64,525 |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock unit represents one share of common stock and converted into common stock upon the termination of Dr. Boger's service on our board of directors on 06/08/2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 21:37 UTC | CervoMed Inc. CRVO · Entity 7338 | PurchaseSeries C Warrants · Derivative | 955,414 | Not disclosed Strike: $3.14 | Not disclosed |
DisclosureSEC source: 0001437749-26-020691 · rdgdoc.xml · derivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 955,414 Underlying: Common Stock · 955,414 shares Expires 2027-06-11 F4 · security: The Series C Warrants have an exercise price equal to $3.14 per share of Common Stock or $3.139 per pre-funded warrant, are exercisable immediately, and will expire one year from the issuance date of the Series C Warrant. F5 · security: Under the terms of the Series B Warrants and the Series C Warrants, the Issuer may not effect the exercise of any portion thereof, and the JSB 2021 Trust will not have the right to exercise any portion thereof, which, upon giving effect to such exercise, would cause the JSB 2021 Trust (together with its affiliates) to own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. To the extent that exercise of the Series B Warrants or Series C Warrants will result in the JSB 2021 Trust (together with its affiliates) beneficially owning shares of Common Stock above such ownership limitations, the JSB 2021 Trust may exercise its Series B Warrants or Series C Warrants for pre-funded warrants to purchase shares of Common Stock, which pre-funded warrants will include a substantially similar maximum ownership limitation. F1 · price: On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase Agreement"), with the Joshua S. Boger 2021 Trust DTD 12/09/2021, of which the Reporting Person serves as the sole trustee (the "JSB 2021 Trust"), and certain accredited investors named therein. Pursuant to the Purchase Agreement, the JSB 2021 Trust purchased an aggregate of 955,414 units (the "Units"), each Unit comprised of (i) one share of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) one Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series B Warrant"), and (iii) one Series C warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series C Warrant") for a purchase price of $3.14 per Unit. F6 · ownership.nature: The Series B Warrants and Series C Warrants are owned by the JSB 2021 Trust. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:37 UTC | CervoMed Inc. CRVO · Entity 7338 | PurchaseSeries B Warrants · Derivative | 955,414 | Not disclosed Strike: $3.32 | Not disclosed |
DisclosureSEC source: 0001437749-26-020691 · rdgdoc.xml · derivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 955,414 Underlying: Common Stock · 955,414 shares Expires 2031-06-11 F3 · security: The Series B Warrants have an exercise price equal to $3.32 per share of Common Stock or $3.319 per pre-funded warrant, are exercisable immediately, and will expire five years from the issuance date of the Series B Warrant. F5 · security: Under the terms of the Series B Warrants and the Series C Warrants, the Issuer may not effect the exercise of any portion thereof, and the JSB 2021 Trust will not have the right to exercise any portion thereof, which, upon giving effect to such exercise, would cause the JSB 2021 Trust (together with its affiliates) to own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. To the extent that exercise of the Series B Warrants or Series C Warrants will result in the JSB 2021 Trust (together with its affiliates) beneficially owning shares of Common Stock above such ownership limitations, the JSB 2021 Trust may exercise its Series B Warrants or Series C Warrants for pre-funded warrants to purchase shares of Common Stock, which pre-funded warrants will include a substantially similar maximum ownership limitation. F1 · price: On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase Agreement"), with the Joshua S. Boger 2021 Trust DTD 12/09/2021, of which the Reporting Person serves as the sole trustee (the "JSB 2021 Trust"), and certain accredited investors named therein. Pursuant to the Purchase Agreement, the JSB 2021 Trust purchased an aggregate of 955,414 units (the "Units"), each Unit comprised of (i) one share of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) one Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series B Warrant"), and (iii) one Series C warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series C Warrant") for a purchase price of $3.14 per Unit. F6 · ownership.nature: The Series B Warrants and Series C Warrants are owned by the JSB 2021 Trust. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:37 UTC | CervoMed Inc. CRVO · Entity 7338 | PurchaseCommon Stock | 955,414 | $3.14 | $2,999,999.96 |
DisclosureSEC source: 0001437749-26-020691 · rdgdoc.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trusts Disclosed balance after: 1,795,865 F1 · shares: On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase Agreement"), with the Joshua S. Boger 2021 Trust DTD 12/09/2021, of which the Reporting Person serves as the sole trustee (the "JSB 2021 Trust"), and certain accredited investors named therein. Pursuant to the Purchase Agreement, the JSB 2021 Trust purchased an aggregate of 955,414 units (the "Units"), each Unit comprised of (i) one share of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) one Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series B Warrant"), and (iii) one Series C warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series C Warrant") for a purchase price of $3.14 per Unit. F1 · price: On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase Agreement"), with the Joshua S. Boger 2021 Trust DTD 12/09/2021, of which the Reporting Person serves as the sole trustee (the "JSB 2021 Trust"), and certain accredited investors named therein. Pursuant to the Purchase Agreement, the JSB 2021 Trust purchased an aggregate of 955,414 units (the "Units"), each Unit comprised of (i) one share of the Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) one Series B warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series B Warrant"), and (iii) one Series C warrant to purchase one share of Common Stock or a pre-funded warrant to purchase one share of Common Stock (each, a "Series C Warrant") for a purchase price of $3.14 per Unit. F2 · ownership.nature: After giving effect to all transactions described herein, consists of (i) 1,600,117 shares of the Issuer's common stock held by the JSB 2021 Trust and (ii) 195,748 shares of the Issuer's common stock held by The Amy S. Boger 2021 Trust (the "ASB 2021 Trust"). The Reporting Person serves as the sole trustee of each of the JSB 2021 Trust and the ASB 2021 Trust. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 23:42 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 8,150 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001437749-26-020211 · rdgdoc.xml · derivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,150 Underlying: Common Stock · 8,150 shares Expires 2036-06-08 F1 · derivative.exercise_date: On June 8, 2026, in connection with the Reporting Person's election to the Issuer's board of directors at its 2026 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,150 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:03 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 8,100 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0001437749-25-021273 · rdgdoc.xml · derivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,100 Underlying: Common Stock · 8,100 shares Expires 2035-06-23 F1 · derivative.exercise_date: On June 23, 2025, in connection with the Reporting Person's election to the Issuer's board of directors at its 2025 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,100 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2025, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 22:27 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 5,750 | $0.00 Strike: $19.01 | $0.00 |
DisclosureSEC source: 0001437749-24-020413 · rdgdoc.xml · derivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,750 Underlying: Common Stock · 5,750 shares Expires 2034-06-14 F1 · derivative.exercise_date: On June 14, 2024, in connection with the Reporting Person's election to the Issuer's board of directors at its 2024 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 5,750 shares of the Issuer's common stock under the Issuer's 2015 Equity Incentive Plan, as amended, in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:02 UTC | CervoMed Inc. CRVO · Entity 7338 | OtherPre-Funded Common Stock Purchase Warrant · Derivative | 495,995 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001437749-24-005918 · rdgdoc.xml · derivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trusts Disclosed balance after: 0 Underlying: Common Stock · 495,995 shares Expires not disclosed F1 · price: On February 26, 2024, a pre-funded common stock purchase warrant to purchase 495,995 shares of the Issuer's common stock (as amended, the "Pre-Funded Warrant") held by the JSB 2021 Trust (as defined below) was amended and subsequently exercised in full on a cashless basis. In accordance with the terms of the Pre-Funded Warrant, 36 shares of the Issuer's common stock were withheld in lieu of a cash payment of the exercise price and the JSB 2021 Trust was issued the remaining 495,959 shares of the Issuer's common stock. F3 · price: Consists of shares of the Issuer's common stock underlying the previously issued Pre-Funded Warrant. The Pre-Funded Warrant is exercisable at any time after the date of issuance and the pre-funded warrants do not expire. F3 · derivative.exercise_date: Consists of shares of the Issuer's common stock underlying the previously issued Pre-Funded Warrant. The Pre-Funded Warrant is exercisable at any time after the date of issuance and the pre-funded warrants do not expire. F3 · derivative.expiration_date: Consists of shares of the Issuer's common stock underlying the previously issued Pre-Funded Warrant. The Pre-Funded Warrant is exercisable at any time after the date of issuance and the pre-funded warrants do not expire. F2 · ownership.nature: After giving effect to all transactions described herein, consists of (i) 644,703 shares of the Issuer's common stock held by The Joshua S. Boger 2021 Trust DTD 12/09/2021 (the "JSB 2021 Trust") and (ii) 195,748 shares of the Issuer's common stock held by The Amy S. Boger 2021 Trust (the "ASB 2021 Trust"). The Reporting Person serves as the sole trustee of each of the JSB 2021 Trust and the ASB 2021 Trust. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:02 UTC | CervoMed Inc. CRVO · Entity 7338 | SaleCommon Stock | 36 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-005918 · rdgdoc.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trusts Disclosed balance after: 840,451 F1 · kind: On February 26, 2024, a pre-funded common stock purchase warrant to purchase 495,995 shares of the Issuer's common stock (as amended, the "Pre-Funded Warrant") held by the JSB 2021 Trust (as defined below) was amended and subsequently exercised in full on a cashless basis. In accordance with the terms of the Pre-Funded Warrant, 36 shares of the Issuer's common stock were withheld in lieu of a cash payment of the exercise price and the JSB 2021 Trust was issued the remaining 495,959 shares of the Issuer's common stock. F1 · price: On February 26, 2024, a pre-funded common stock purchase warrant to purchase 495,995 shares of the Issuer's common stock (as amended, the "Pre-Funded Warrant") held by the JSB 2021 Trust (as defined below) was amended and subsequently exercised in full on a cashless basis. In accordance with the terms of the Pre-Funded Warrant, 36 shares of the Issuer's common stock were withheld in lieu of a cash payment of the exercise price and the JSB 2021 Trust was issued the remaining 495,959 shares of the Issuer's common stock. F2 · ownership.nature: After giving effect to all transactions described herein, consists of (i) 644,703 shares of the Issuer's common stock held by The Joshua S. Boger 2021 Trust DTD 12/09/2021 (the "JSB 2021 Trust") and (ii) 195,748 shares of the Issuer's common stock held by The Amy S. Boger 2021 Trust (the "ASB 2021 Trust"). The Reporting Person serves as the sole trustee of each of the JSB 2021 Trust and the ASB 2021 Trust. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:02 UTC | CervoMed Inc. CRVO · Entity 7338 | OtherCommon Stock | 495,995 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-005918 · rdgdoc.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trusts Disclosed balance after: 840,487 F1 · shares: On February 26, 2024, a pre-funded common stock purchase warrant to purchase 495,995 shares of the Issuer's common stock (as amended, the "Pre-Funded Warrant") held by the JSB 2021 Trust (as defined below) was amended and subsequently exercised in full on a cashless basis. In accordance with the terms of the Pre-Funded Warrant, 36 shares of the Issuer's common stock were withheld in lieu of a cash payment of the exercise price and the JSB 2021 Trust was issued the remaining 495,959 shares of the Issuer's common stock. F1 · price: On February 26, 2024, a pre-funded common stock purchase warrant to purchase 495,995 shares of the Issuer's common stock (as amended, the "Pre-Funded Warrant") held by the JSB 2021 Trust (as defined below) was amended and subsequently exercised in full on a cashless basis. In accordance with the terms of the Pre-Funded Warrant, 36 shares of the Issuer's common stock were withheld in lieu of a cash payment of the exercise price and the JSB 2021 Trust was issued the remaining 495,959 shares of the Issuer's common stock. F2 · ownership.nature: After giving effect to all transactions described herein, consists of (i) 644,703 shares of the Issuer's common stock held by The Joshua S. Boger 2021 Trust DTD 12/09/2021 (the "JSB 2021 Trust") and (ii) 195,748 shares of the Issuer's common stock held by The Amy S. Boger 2021 Trust (the "ASB 2021 Trust"). The Reporting Person serves as the sole trustee of each of the JSB 2021 Trust and the ASB 2021 Trust. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 12, 2024 Filed Feb 13, 2024 21:39 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.97 | $0.00 |
DisclosureSEC source: 0001437749-24-003927 · rdgdoc.xml · derivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-02-12 F1 · derivative.exercise_date: On February 12, 2024, in connection with the Reporting Person's initial election to the Issuer's board of directors, the Reporting Person was granted an option to purchase 10,000 shares of the Issuer's common stock under the Issuer's 2015 Equity Incentive Plan, as amended, in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a three-year period in substantially equal 1/36th increments on the last day of each month beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 20:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionDeferred Stock Units · Derivative | 2,941 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-038895 · doc4.xml · derivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,941 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and converted into common stock upon the termination of Dr. Boger's service on our board of directors on 06/08/2017. F1 · price: Each deferred stock unit represents one share of common stock and converted into common stock upon the termination of Dr. Boger's service on our board of directors on 06/08/2017. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and converted into common stock upon the termination of Dr. Boger's service on our board of directors on 06/08/2017. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and converted into common stock upon the termination of Dr. Boger's service on our board of directors on 06/08/2017. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 20:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,941 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-038895 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents one share of common stock and converted into common stock upon the termination of Dr. Boger's service on our board of directors on 06/08/2017. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 2,941 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-037808 · doc4.xml · derivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,941 Underlying: Common Stock · 2,941 shares Expires not disclosed F4 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Boger's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Boger's disability or death. F2 · price: Upon the vesting of restricted stock units granted to Dr. Boger on June 1, 2016, Dr. Boger deferred the receipt of 2,941 shares of common stock and received instead 2,941 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Dr. Boger is reporting the disposition of 2,941 shares of common stock in exchange for an equal number of deferred stock units. F4 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Boger's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Boger's disability or death. F4 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Boger's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Boger's disability or death. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 5,295 | $0.00 Strike: $125.71 | $0.00 |
DisclosureSEC source: 0001209191-17-037808 · doc4.xml · derivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,295 Underlying: Common Stock · 5,295 shares Expires 2027-05-31 F3 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Disposition to issuerCommon Stock | 2,941 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-037808 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,147 F2 · price: Upon the vesting of restricted stock units granted to Dr. Boger on June 1, 2016, Dr. Boger deferred the receipt of 2,941 shares of common stock and received instead 2,941 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Dr. Boger is reporting the disposition of 2,941 shares of common stock in exchange for an equal number of deferred stock units. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-037808 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,088 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $36.30 | $0.00 |
DisclosureSEC source: 0001209191-17-003660 · doc4.xml · derivative · entry 9 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2017-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $84.98 | $42,490.00 |
DisclosureSEC source: 0001209191-17-003660 · doc4.xml · nonDerivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,225 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $84.98 (range $84.87 to $85.11). Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,100 | $84.41 | $92,851.00 |
DisclosureSEC source: 0001209191-17-003660 · doc4.xml · nonDerivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,725 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $84.41 (range $83.72 to $84.70). Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,100 | $82.92 | $91,212.00 |
DisclosureSEC source: 0001209191-17-003660 · doc4.xml · nonDerivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,825 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $82.92 (range $82.64 to $83.24). Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,900 | $82.17 | $238,293.00 |
DisclosureSEC source: 0001209191-17-003660 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,925 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $82.17 (range $81.62 to $82.55). Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,400 | $81.25 | $195,000.00 |
DisclosureSEC source: 0001209191-17-003660 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,825 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $81.25 (range $80.61 to $81.60). Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 8,000 | $36.30 | $290,400.00 |
DisclosureSEC source: 0001209191-17-003660 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 18:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $36.30 | $0.00 |
DisclosureSEC source: 0001209191-17-002576 · doc4.xml · derivative · entry 7 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 6,500 shares Expires 2017-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 18:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,900 | $77.69 | $147,611.00 |
DisclosureSEC source: 0001209191-17-002576 · doc4.xml · nonDerivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,225 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $77.69 (range $77.41 to $78.04). Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 18:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,400 | $76.95 | $338,580.00 |
DisclosureSEC source: 0001209191-17-002576 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,125 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $76.95 (range $76.35 to $77.28). Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 18:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $75.64 | $15,128.00 |
DisclosureSEC source: 0001209191-17-002576 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,525 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $75.64 (range $75.22 to $76.06). Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 18:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,500 | $36.30 | $235,950.00 |
DisclosureSEC source: 0001209191-17-002576 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 29, 2016 Filed Jan 3, 2017 21:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $36.30 | $0.00 |
DisclosureSEC source: 0001209191-17-000287 · doc4.xml · derivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 6,500 shares Expires 2017-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| December 29, 2016 Filed Jan 3, 2017 21:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 800 | $74.86 | $59,888.00 |
DisclosureSEC source: 0001209191-17-000287 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,225 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $74.86 (range $74.80 to $74.91). Read SEC document |
| December 29, 2016 Filed Jan 3, 2017 21:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,700 | $74.25 | $423,225.00 |
DisclosureSEC source: 0001209191-17-000287 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,025 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $74.25 (range $73.76 to $74.75). Read SEC document |
| December 29, 2016 Filed Jan 3, 2017 21:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,500 | $36.30 | $235,950.00 |
DisclosureSEC source: 0001209191-17-000287 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2016 Filed Dec 22, 2016 15:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $36.30 | $0.00 |
DisclosureSEC source: 0001209191-16-156413 · doc4.xml · derivative · entry 8 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 6,500 shares Expires 2017-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| December 21, 2016 Filed Dec 22, 2016 15:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $76.39 | $22,917.00 |
DisclosureSEC source: 0001209191-16-156413 · doc4.xml · nonDerivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,225 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $76.39 (range $76.13 to $76.52). Read SEC document |
| December 21, 2016 Filed Dec 22, 2016 15:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 800 | $75.61 | $60,488.00 |
DisclosureSEC source: 0001209191-16-156413 · doc4.xml · nonDerivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,525 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $75.61 (range $75.12 to $76.03). Read SEC document |
| December 21, 2016 Filed Dec 22, 2016 15:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,300 | $74.35 | $96,655.00 |
DisclosureSEC source: 0001209191-16-156413 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,325 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $74.35 (range $74.07 to $75.00). Read SEC document |
| December 21, 2016 Filed Dec 22, 2016 15:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,100 | $73.65 | $301,965.00 |
DisclosureSEC source: 0001209191-16-156413 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,625 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $73.65 (range $73.06 to $74.05). Read SEC document |
| December 21, 2016 Filed Dec 22, 2016 15:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,500 | $36.30 | $235,950.00 |
DisclosureSEC source: 0001209191-16-156413 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 20:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $36.30 | $0.00 |
DisclosureSEC source: 0001209191-16-155612 · doc4.xml · derivative · entry 6 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 6,500 shares Expires 2017-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 20:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 800 | $78.22 | $62,576.00 |
DisclosureSEC source: 0001209191-16-155612 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,225 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $78.22 (range $77.89 to $78.57). Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 20:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,700 | $77.42 | $441,294.00 |
DisclosureSEC source: 0001209191-16-155612 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,025 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $77.42 (range $76.89 to $77.84). Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 20:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,500 | $36.30 | $235,950.00 |
DisclosureSEC source: 0001209191-16-155612 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 19:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $36.30 | $0.00 |
DisclosureSEC source: 0001209191-16-154333 · doc4.xml · derivative · entry 7 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 6,500 shares Expires 2017-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 19:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $76.20 | $7,620.00 |
DisclosureSEC source: 0001209191-16-154333 · doc4.xml · nonDerivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,225 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 19:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,800 | $75.48 | $286,824.00 |
DisclosureSEC source: 0001209191-16-154333 · doc4.xml · nonDerivative · entry 3 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,325 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $75.48 (range $75.17 to $76.13). Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 19:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,600 | $74.63 | $194,038.00 |
DisclosureSEC source: 0001209191-16-154333 · doc4.xml · nonDerivative · entry 2 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,125 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $74.63 (range $74.15 to $75.12). Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 19:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,500 | $36.30 | $235,950.00 |
DisclosureSEC source: 0001209191-16-154333 · doc4.xml · nonDerivative · entry 1 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 19:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $36.30 | $0.00 |
DisclosureSEC source: 0001209191-16-152916 · doc4.xml · derivative · entry 8 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,500 Underlying: Common Stock · 6,500 shares Expires 2017-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 19:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $85.53 | $42,765.00 |
DisclosureSEC source: 0001209191-16-152916 · doc4.xml · nonDerivative · entry 5 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,225 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $85.53 (range $85.35 to $85.85). Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 19:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,700 | $84.53 | $143,701.00 |
DisclosureSEC source: 0001209191-16-152916 · doc4.xml · nonDerivative · entry 4 BOGER JOSHUA S · CIK 0001197023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,725 F1 · kind: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $84.53 (range $84.14 to $85.00). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.